Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.

① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?

cls.cnApr 24 03:37 ET

SIHUAN PHARM (00460.HK): The dapagliflozin tablets developed by Huisheng Bio have been approved for market launch by the National Medical Products Administration.

On April 23, Gelonghui reported that SIHUAN PHARM (00460.HK) announced that its non-wholly-owned subsidiary, Huisheng Biopharmaceutical Co., Ltd., developed Dapagliflozin tablets, which have been granted a drug registration certificate by China's National Medical Products Administration for adults with type 2 diabetes, considered equivalent to passing the consistency evaluation for generic drug quality and efficacy. Dapagliflozin tablets are the first SGLT-2 (sodium-glucose co-transporter-2) inhibitor approved for marketing globally. SGLT-2 inhibitors are currently highly recommended as a novel oral hypoglycemic medication for treating type 2 diabetes, selectively inhibiting renal proximal...

Gelonghui FinanceApr 23 08:43 ET

Express News | Sihuan Pharma - Dapagliflozin Tablets Developed by Huisheng Biopharmaceutical Obtained Drug Registration Approval From Nmpa

ReutersApr 23 08:38 ET

Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.

① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?

cls.cnApr 21 23:57 ET

Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.

As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.

cls.cnApr 16 20:31 ET

Express News | Sihuan Pharma - Repurchased 10 Mln Shares at Average Price of HK$0.6274 per Share

ReutersApr 16 06:40 ET